Forbion Capital Partners Investor
Forbion Capital Partners is a venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Invests into
Investors
Headquarters:
Naarden,Noord-Holland,The Netherlands,Europe
Employee Number:
11-50
Industry:
RNA & Oligonucleotide Medicines
Number Of Exists:
37
Investor Type:
Venture Funds
Founded Date:
2006-01-01
Funding Status:
private